Exploring Best Practices for Diagnosis and Management of Hypereosinophilic Syndrome

To participate in this activity, please:

Hypereosinophilic syndromes (HESs) are a broad group of disorders that can lead to serious complications, including cardiovascular disease, cerebrovascular disease, and death. Due to their rarity, however, HESs are challenging to diagnose and treat. In this in-depth review, presented by Princess Ogbogu, MD, and developed in collaboration with Michael Wechsler, MD, MMSc, the wide-ranging presentations of HES will be reviewed, along with pathophysiology, classification, and acute and chronic management. Learnings from the presentation will be tied together with a case-based presentation of idiopathic HES, allowing learners to see how guideline recommendations and novel clinical trials can be applied in a real clinical setting.

This program is also available as a podcast.  You may download it here: https://anchor.fm/hypereosinophilicsyndrome 

Course Credit:

1.00 ACPE Contact Hour
1.00 AMA PRA Category 1 CreditTM
1.00 ANCC Contact Hour
1.00 CA-BRN Contact Hour


Opens: 2021-06-30
Closes: 2022-06-30

Target Audience:

This activity is intended for allergists, immunologists, pulmonologists, along with other specialists and clinicians involved in the diagnosis and management of patients with hypereosinophilic syndrome.

This educational activity is supported by an educational grant from GlaxoSmithKline.

    Presenting Faculty

  • Princess Ogbogu, MD

    Chief of the Division of Allergy, Immunology, and Rheumatology
    University Hospitals Rainbow Babies & Children’s Hospital
    Cleveland, Ohio

  • Michael E. Wechsler, MD, MMSc

    Professor of Medicine
    Director, Cohen Family NJH Asthma Institute
    Director, Asthma Program, National Jewish Health
    Division of Pulmonary, Critical Care and Sleep Medicine
    Department of Medicine
    National Jewish Health and University of Colorado School of Medicine
    Denver, Colorado

Learning Objectives

  • Describe the mechanism of eosinophilia in HES and how this can be targeted using biologic agents
  • Perform differential diagnosis of eosinophilic disorders to identify patients with hypereosinophilic syndrome (HES)
  • Develop patient-specific treatment plans based on HES subtype
  • Discuss the safety and efficacy of new and emerging biologic treatments for HES

Faculty Disclosures

Princess Ogbogu, MD

Advisory Board: AstraZeneca, GlaxoSmithKline, Sanofi

Clinical Trial: AstraZeneca

Michael E. Wechsler, MD, MMSc

Consultant: GlaxoSmithKline, AstraZeneca, Sanofi, Regeneron, Genzyme, Novartis, Genentech, Boehringer Ingelheim, Sentien, COhero, Equillium

Speakers Bureau: AstraZeneca, GlaxoSmithKline, Sanofi, Regeneron, Genzyme

Accreditation and Certification

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program has been assigned ACPE Universal Program #. This program is designated for up to 1.00 contact hour (0.1 CEUs) of continuing pharmacy education credit.
The Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
A maximum of 1.00 contact hour may be earned for successful completion of this activity.
Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.00 contact hour.
To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.

Additional Content Planners

Jessica Martin, PhD (Medical Writer)
No significant relationships to disclose.

Kam A. Newman, MD (Peer Reviewer)
No significant relationships to disclose.

Annenberg Center for Health Sciences

Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.